December - 2016

Sales exceed $2 Million for first year of Profounda's Commercial Presence in the USA

Sales of Impavido, Rhinase Soothing Nasal Gel and Rhinase Lubricating Mist exceeded $2.5 M for 2016 making it a great start for Profounda...

Orphan drug status approval for Acanthamoeba Keratitis received by Profounda for Miltefosine

Orphan indication received by Profounda is for the treatment of Acanthamoeba Keratitis, also commonly known as AK usually associated with...

Profounda Inc. receives FDA orphan-drug designation for the Treatment of Primary Amebic Meningoencep

Orphan indication received by Profounda is for the treatment of PAM, also commonly known as the Brain Eating Amoeba ORLANDO, Fla. Dec ...

Here we come 2023!

Generic to Arestin Microspheres by Bausch Health (Orapharma) receives Competitive Generic Therapy De

DOG AND HUMANS GET GREAT RESULTS

Sales exceed $2 Million for first year of Profounda's Commercial Presence in the USA

Orphan drug status approval for Acanthamoeba Keratitis received by Profounda for Miltefosine

Profounda Inc. receives FDA orphan-drug designation for the Treatment of Primary Amebic Meningoencep

CNN report on Survivor of Brain Eating Amoeba

Patient survives Brain Eating Amoeba

Profounda working with local Health Officials in fight to save patients life.

Profounda Licensed in Florida

PROFOUNDA, INC.